As the basic needs of human beings, the rigid characteristics of medical and health care are becoming increasingly prominent. Health and health expenditure is closely related to the growth of residents' income, and is also affected by people's living standards and health awareness. Data show that as of 2020, the number of medical and health institutions in China has reached 1,023,000, with an average growth rate of 011%。In recent years, the state's investment in medical and health institutions has increased, and medical and health issues related to the national economy and people's livelihood will continue to increase.
In the context of China's growing demand for medical and health care, Haier Capital, the investment platform of Haier Jinying, has attracted widespread attention in the field of healthcare in recent years. Over the years, Haier Capital has been focusing on industrial investment, especially in cutting-edge hard-core tracks such as healthcare and intelligent technology. By providing differentiated post-investment management for co-creators, Haier Capital not only assists in the linkage of industrial resources and value reconstruction, but also accelerates the full implementation of the industrial ecosystem.
In the recently released "2022-2023 Pharmaceutical and Health Investment Competitiveness Research Case", Haier Capital was once again commended for its investment performance and co-creation achievements in the medical and health field, and was listed in the "Top 30 Venture Capital and Private Equity Investment Institutions in Pharmaceutical and Health Investment Competitiveness". This is not only an affirmation of Haier Capital's past performance, but also an optimism about its future development potential.
Take Haier Capital's excellent co-creation case - Shanghai Cell as an example. Shanghai Cell is currently the only comprehensive medical group in the field of cell **, and the company's core Bai Ze plan is committed to making 60% of the people affordable to cure cancer, and 60% of cancer patients have regression. Haier Capital provides empowering investment for Shanghai Cell from three aspects: capital, ecology and management, grows together with the invested companies, and helps the industry to upgrade and iterate. At present, Shanghai Cell has formed a perfect closed-loop ecology of "the country's largest immune cell storage platform, Mengchao Cancer Hospital, and cell drug R&D platform".
Under the concept of sticking to its original intention, Haier Capital will continue to practice the co-creation model of industrial ecological investment. By working with high-growth value enterprises in various tracks to create symbiosis, Haier Capital will continue to actively empower the real economy and make more contributions to China's medical and health industry and intelligent technology innovation.